Gabapentin Early-Onset Dementia Lawsuit
What Is Gabapentin?
Gabapentin (commonly sold under the brand name Neurontin) is an anticonvulsant and nerve pain medication originally approved by the FDA to treat partial seizures and postherpetic neuralgia. Over time, pharmaceutical manufacturers heavily promoted Gabapentin off-label for unapproved conditions, including general neuropathic pain, fibromyalgia, chronic back pain, and anxiety. Millions of patients take Gabapentin long-term without adequate warning that repeated exposure may pose severe risks to long-term neurocognitive health.
What Injuries Does Gabapentin Cause?
Clinical research highlights a strong, dose-dependent link between long-term Gabapentin usage and accelerated cognitive decline, specifically early-onset dementia and mild cognitive impairment (MCI) in patients under 65.
Clinical Evidence Overview
A landmark nationwide cohort study published in Regional Anesthesia & Pain Medicine (Eghrari et al., July 2025) evaluated over 26,000 patients prescribed Gabapentin for persistent pain. The study confirmed significant risks of neurocognitive decline directly associated with prescription volume.
| Prescription Volume | Dementia Risk Factor | Mild Cognitive Impairment (MCI) Risk | Primary Supporting Study |
|---|---|---|---|
| 1–3 Prescriptions | Baseline | Baseline | Baseline control cohort |
| 6+ Prescriptions | +29% Risk | +85% Risk | Eghrari et al. (Regional Anesthesia & Pain Med, 2025) |
| 12+ Prescriptions | +40% Risk | +65% Risk | Eghrari et al. (Regional Anesthesia & Pain Med, 2025) |
Key Medical Findings & Biological Mechanisms
- Elevated Dementia & MCI Risk: Receiving 6 or more Gabapentin refills increases the 10-year risk of developing dementia by 29% and raises the risk of mild cognitive impairment (MCI) by 85%. Patients filling 12 or more prescriptions face a 40% increased risk of dementia.
- High Susceptibility in Younger Adults: Non-elderly adults (aged 35–49) taking Gabapentin experienced more than double the risk of dementia and more than triple the risk of MCI compared to non-users in the same age demographic.
- Long-Term Mechanism: Research published in Frontiers in Pharmacology and PMC journals indicates that Gabapentin disrupts the alpha-2-delta subunit of voltage-gated calcium channels. Over time, altering calcium signaling impairs synaptic plasticity—the brain’s capacity to form new neural connections, process information, and store memories.
Symptoms of Gabapentin-Related Cognitive Injury: Severe short-term memory loss, persistent brain fog, executive dysfunction, word-finding difficulty, and loss of motor balance.
Who Qualifies to File a Gabapentin Claim?
You or a loved one may qualify to file a Gabapentin lawsuit if you meet the following criteria:
- Prescription History: You were prescribed and regularly took Gabapentin (Neurontin) over an extended period (typically 6 or more prescription refills).
- Diagnosed Injury: You received a formal medical diagnosis of early-onset dementia, Alzheimer’s disease, or severe mild cognitive impairment (MCI) (particularly if diagnosed before age 65).
- Temporal Link: Cognitive symptoms and formal diagnosis developed during or following long-term Gabapentin therapy.
What Is the Current Litigation Status?
Nigh Goldenberg Raso & Vaughn (NGRV) is actively investigating claims nationwide against Gabapentin manufacturers for failure to warn healthcare providers and consumers about the link between extended drug use and severe neurocognitive decline. Lawsuits allege that pharmaceutical manufacturers aggressively promoted off-label uses while withholding critical safety data regarding long-term central nervous system risks.
These claims are handled as individual lawsuits consolidated under Multi-District Litigation (MDL) frameworks rather than class actions. In a mass tort MDL, each plaintiff maintains an independent case, ensuring financial compensation is evaluated based on their specific medical expenses, degree of cognitive decline, and personal damages.
What Can I Expect If I File?
When you partner with Nigh Goldenberg Raso & Vaughn, our legal team manages every stage of the legal and medical evaluation process:
-
Step 1Free Claim EvaluationWe review your prescription history and diagnostic records at no cost to verify your case eligibility.
-
Step 2Evidence & Record CollectionOur legal team secures complete medical charts, pharmacy fill histories, and neurological diagnostic reports on your behalf.
-
Step 3Claim Filing & AdvocacyYour lawsuit is formally prepared and filed against the responsible pharmaceutical manufacturers.
-
Step 4No Upfront FeesNGRV operates strictly on a contingency fee basis. You pay zero legal fees or out-of-pocket costs unless we recover financial compensation for your claim.
Scientific Evidence & Medical References
Our legal strategy is supported by peer-reviewed clinical studies and medical research:
-
July 2025 Risk of dementia following gabapentin prescription in chronic low back pain patients (Eghrari et al.)BMJ Journal Citation
-
Medical Study The association between Gabapentin use and risk of cognitive decline (Oh, et al.)PMC Article Citation
-
Clinical Standard AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older AdultsAmerican Geriatrics Society
